In September last year, AbbVie and Amgen entered into comprehensive settlement agreements in an intellectual property dispute over a biosimilar proposed by Humira. If successful in its litigation, Boehringer`s Cyltezo would be the first biosimilar to enter a US market worth $13.6 billion (11.9 billion euros) in 2018. The transaction transactions for AbbVie were quickly concluded after the agreement with Pfizer was reached shortly before an agreement with Momenta Pharmaceuticals, which advanced the marketing of AbbVie`s copy (adalimumab) of that company until November 2023. As part of the licensing agreement, Pfizer can market its imitation drug in Europe from November 20, 2023, after approval by the EMA and the United States. All ongoing disputes between the parties are now withdrawn. But the first three months of 2019 began to show the effect of biosimilars. In the first months of accession to Europe, total sales decreased by 6% compared to the same period in the previous year. European sales of brand biologism fell by more than 25%. There are other important differences between the biosimilar markets of adalimumab and infliximab. For example, the two agents use different management methods that require different pricing structures. If you look at their brand counterparts, Remicade is much lower than TNF subsane inhibitors like Humira to offset its infusion cost.

Due to the need to lower the price of the drug, there may be thinner margins in which the price of the infliximab to discount and maintain profitability. Another factor that may characterize adalimumab biosimilars is the massive size of the Humira market compared to Remicade. The volume of patients taking Humira can make it easier for biosimilar developers to rent their therapies competitively while making a profit. With the introduction of Mylan`s Biosimilar product after the license opens on July 31, 2023, the company will be required to pay royalties to AbbVie for the licensing of Humira patents. Biologic drugs have changed standards of care for patients with autoimmune diseases. However, the considerable costs associated with the development and manufacture of these complex drugs have led to an explosion in the cost of managing these patients. While stakeholders had hoped that the introduction of biosimilars would help address rising health costs through competitive prices, it has not yet had the desired effect in the United States. In particular, the ingestion of biosimilars on J-Js Remicade (Infliximab) remains recalcitrant.